Janus Henderson Group
AKBA icon

Janus Henderson Group’s Akebia Therapeutics AKBA Stock Holding History

Janus Henderson Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-704,020
Closed -$1.13M – 2407
2025
Q4 		$1.13M Buy
704,020
+588,747
+511% +$1.23M ﹤0.01% 1607
2025
Q3 		$315K Buy
+115,273
New +$383K ﹤0.01% 2192
2022
Q2 		– Sell
-29,784
Closed -$22K – 2594
2022
Q1 		$22K Buy
29,784
+9
+0% +$19 ﹤0.01% 2634
2021
Q4 		$67K Buy
29,775
+15,030
+102% +$41K ﹤0.01% 2527
2021
Q3 		$42K Buy
+14,745
New +$42.1K ﹤0.01% 2180

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group's AKBA Position: Q1 2026 in Review

Janus Henderson Group sold out of Akebia Therapeutics (AKBA) in Q1 2026, closing a stake of 704,020 shares — an estimated $1.13M sold.

Janus Henderson Group first reported a position in AKBA in Q3 2021 and held it in 5 quarters. The position peaked at $1.13M in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Janus Henderson Group reported no remaining Akebia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Janus Henderson Group sold 704,020 Akebia Therapeutics shares in Q1 2026, an estimated $1.13M.
  • Janus Henderson Group first reported a position in Akebia Therapeutics in Q3 2021 and held it in 5 quarters.
  • Janus Henderson Group's Akebia Therapeutics position peaked at $1.13M in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.